On May 16, 2016, Revive Therapeutics Ltd. (TSXV:  RVV) announced a best efforts rights offering to raise $2.2 million.  Revive is focused on commercializing treatments for gout, and rare diseases such as cystinuria, Wilson’s disease and Rett syndrome.

Peterson & Company LLP acted for Revive with a team that included Dennis Peterson.